RLRu Li

Ru Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ru Li has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Zhang

    Department of Pharmacology, School of Basic Medicine, Shanxi Medical University, Taiyuan 030001, China

    6 shared publications
  • Baofeng Wu

    Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China

    5 shared publications
  • Yunfeng Liu

    Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China

    4 shared publications
  • Ming Xu

    Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China

    3 shared publications
  • Hongxia Wei

    Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China

    2 shared publications
  • Jinxuan Hao

    Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China

    2 shared publications

Latest Publications

  • Open Access

    Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19

    by Baofeng Wu, Ru Li, Qinhao Liu, Shuqing Jin, Hongxia Wei, Ming Xu, Yi Zhang, Yunfeng Liu

    The pituitary gland is a very important endocrine gland in the human body. It secretes and releases many hormones crucial for controlling physiological processes, such as energy metabolism, human growth and development, and reproduction. The renin-angiotensin-aldosterone system regulates water and salt homeostasis, controlling blood pressure. Since the discovery of the renin-angiotensin-aldosterone system, exploring and studying its role in pathophysiology has never stopped, and patients have benefited from drug-based and clinical studies. This review focuses on the effects of the pituitary-target gland axis (pituitary-thyroid axis, pituitary-adrenal axis, pituitary-growth hormone axis, pituitary-gonadal axis) and some hormones secreted and stored by the pituitary gland on the RAAS. While considering that SARS-CoV-2 reinfection still occurs, we aim to provide new insights into water-electrolyte balance and blood pressure regulation.

  • Open Access

    Current evidence and strategies for preventing tumor recurrence following thermal ablation of papillary thyroid carcinoma

    by Ru Li, Luyang Yang, Ming Xu, Baofeng Wu, Qinhao Liu, Qin An, Yuchen Sun, Yi Zhang, Yunfeng Liu

    Background: The incidence of papillary thyroid carcinoma (PTC) has been increasing, and thermal ablation has emerged as a minimally invasive alternative to surgery for low-risk cases. However, post-ablation tumor progression remains a significant clinical challenge. Methods: This review synthesizes existing literature on tumor progression after thermal ablation for PTC, analyzing potential causes and evaluating preventive strategies at different diagnostic and treatment stages. Results: Current research reports indicate that the probability of disease progression following thermal ablation for PTMC ranges from 1.25 to 7.7%, a rate comparable to that of surgical management. Nodules exceeding 10 mm in diameter are associated with a higher risk of post-procedural progression. However, pathological evidence supporting these findings remains limited. Risk factors such as suboptimal patient selection and tumor proximity to critical structures further influence outcomes. Improved imaging guidance, standardized protocols, and stringent follow-up may reduce these complications. Conclusion: When these recommendations are followed, thermal ablation for PTMC achieves effective reduction in tumor progression risk and represents a viable alternative for appropriately selected patients. However, expansion of its indications requires further robust evidence from large-scale, pathology-based studies.


  • Open Access

    Causal effects of gut microbiota on diabetic neuropathy: a two-sample Mendelian randomization study

    by Ming Xu, Jinxuan Hao, Yijie Qi, Baofeng Wu, Ru Li, Xifeng Yang, Yi Zhang, Yunfeng Liu

    Objective: Previous observational studies have suggested an association between gut microbiota and diabetic neuropathy (DN). However, confounding factors and reverse causality make the causal relationship between gut microbiota and DN uncertain. We aimed to investigate the interactive causal relationships between the abundance of gut microbiota and DN.Methods: We conducted a Mendelian randomization (MR) analysis to examine the causal relationship between gut microbiota and DN. Genomic data on gut microbiota at the genus level were obtained from the MiBioGen Consortium, including 18,340 individuals of European descent. Data on diabetic polyneuropathy (DPN) were obtained from the FinnGen Consortium, which included 1,048 cases and 374,434 controls, while data on diabetic autonomic neuropathy (DAN) were also obtained from the FinnGen Consortium, including 111 cases and 374,434 controls. Causal effects were primarily estimated using inverse variance weighted (IVW) analysis, supplemented with four validation methods, and additional sensitivity analyses to assess the pleiotropy, heterogeneity, and robustness of instrumental variables.Results: The IVW analysis indicated that Prevotella 9 had a protective effect on DPN (OR = 0.715, 95% CI: 0.521-0.982, P = 0.038), and Bacteroides also showed a protective effect (OR = 0.602, 95% CI: 0.364-0.996, P = 0.048). On the other hand, Ruminococcus 2 had a promoting effect on DPN (OR = 1.449, 95% CI: 1.008-2.083, P = 0.045). Blautia (OR = 0.161, 95% CI: 0.035-0.733, P = 0.018), Clostridium innocuum group (OR = 3.033, 95% CI: 1.379-6.672, P = 0.006), and Howardella (OR = 2.595, 95% CI: 1.074-6.269, P = 0.034) were causally associated with DAN in the IVW analysis, with no evidence of heterogeneity or pleiotropy. Sensitivity analyses showed no significant pleiotropy or heterogeneity.Conclusion: Our study identified a causal relationship between gut microbiota and the increased or decreased risk of diabetic neuropathy. These findings underscore the importance of adopting a comprehensive approach that combines gut microbiota modulation with other therapeutic interventions in the management of diabetic neuropathy.


  • Open Access

    CT semi-quantitative score used as risk factor for hyponatremia in patients with COVID-19: a cross-sectional study

    by Baofeng Wu, Ru Li, Jinxuan Hao, Yijie Qi, Botao Liu, Hongxia Wei, Zhe Li, Yi Zhang, Yunfeng Liu

    Purpose: Chest computed tomography (CT) is used to determine the severity of COVID-19 pneumonia, and pneumonia is associated with hyponatremia. This study aims to explore the predictive value of the semi-quantitative CT visual score for hyponatremia in patients with COVID-19 to provide a reference for clinical practice.Methods: In this cross-sectional study, 343 patients with RT-PCR confirmed COVID-19, all patients underwent CT, and the severity of lung lesions was scored by radiologists using the semi-quantitative CT visual score. The risk factors of hyponatremia in COVID-19 patients were analyzed and combined with laboratory tests. The thyroid function changes caused by SARS-CoV-2 infection and their interaction with hyponatremia were also analyzed.Results: In patients with SARS-CoV-2 infection, the total severity score (TSS) of hyponatremia was higher [M(range), 3.5(2.5–5.5) vs 3.0(2.0–4.5) scores, P=0.001], implying that patients with hyponatremia had more severe lung lesions. The risk factors of hyponatremia in the multivariate regression model included age, vomiting, neutrophils, platelet, and total severity score. SARS-CoV-2 infection impacted thyroid function, and patients with hyponatremia showed a lower free triiodothyronine (3.1 ± 0.9 vs 3.7 ± 0.9, P=0.001) and thyroid stimulating hormone level [1.4(0.8–2.4) vs 2.2(1.2–3.4), P=0.038].Conclusion: Semi-quantitative CT score can be used as a risk factor for hyponatremia in patients with COVID-19. There is a weak positive correlation between serum sodium and free triiodothyronine in patients with SARS-CoV-2 infection.


  • Open Access

    Uric Acid Metabolic Disorders in Pituitary-Target Gland Axis

    by Ru Li, Baofeng Wu, Minmin Han, Mengnan Li, Xifeng Yang, Jian Zhang, Yi Zhang, Yunfeng Liu

    Uric acid (UA) is the end product of purine metabolism in the human, and the imbalance between production and excretion results in the disturbance of serum uric acid (SUA). There is evidence suggesting that pituitary-target gland hormones can affect UA metabolism through regulating the activity of xanthine oxidase and UA transporters. Related endocrine diseases including thyroid dysfunction, polycystic ovary syndrome, acromegaly and Cushing’s syndrome are often accompanied by elevated UA levels. In addition to the direct influence of abnormal hormones, obesity and insulin resistant play a pivotal role. Diabetes insipidus and the syndrome of inappropriate antidiuretic hormone secretion also present with abnormal SUA levels due to the action of antidiuretic hormone. However, certain evidence within the population is disputed. This review summarized the effects of pituitary-target gland hormones on UA metabolism, and preliminarily described the related mechanisms, offering a theoretical foundation for assessing SUA in endocrine disorders as well as guiding its management.


  • Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials

    by Mengnan Li, Guimei Yang, Jiaxin Zhang, Minmin Han, Yi Zhang, Yunfeng Liu

    Aims Several trials have assessed the antihyperglycemic effects of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) in patients with type 2 diabetes mellitus (T2DM). We conducted a quantitative analysis to assess the effects of SGLT2Is on renal risk factors in patients with abnormal glucose metabolism. Materials and methods Randomized controlled trials (RCTs) were identified by searching the PubMed, Embase, Scopus, and Web of Science databases published before September 30, 2022. The intervention group received SGLT2Is as monotherapy or add-on treatment, and the control group received placebos, standard care, or active control. Risk of bias assessment was performed using the Cochrane risk of bias assessment tool. Meta-analysis was performed on studies with abnormal glucose metabolism populations and studies using the weighted mean differences (WMDs) as the measure of the effect size. Clinical trials providing changes in serum uric acid (SUA) were included. The mean change of SUA, glycated hemoglobin (HbA1c), body mass index (BMI), and estimated glomerular filtration rate (eGFR) were calculated. Results After a literature search and detailed evaluation, a total of 11 RCTs were included for quantitative analysis to analyze the differences between the SGLT2I group and the control group. The results showed that SGLT2I significantly reduced SUA (MD = −0.56, 95% CI = −0.66 ~ −0.46, I2 = 0%, P < 0.00001), HbA1c (MD = −0.20, 95% CI = −0.26 ~ −0.13, I2 = 0%, P < 0.00001), and BMI (MD = −1.19, 95% CI = −1.84 ~ −0.55, I2 = 0%, P = 0.0003). There was no significant difference in the reduction of eGFR observed in the SGLT2I group (MD = −1.60, 95% CI = −3.82 ~ 0.63, I2 = 13%, P = 0.16). Conclusions These results showed that the SGLT2I group caused greater reductions in SUA, HbA1c, and BMI but had no effect on eGFR. These data suggested that SGLT2Is may have numerous potentially beneficial clinical effects in patients with abnormal glucose metabolism. However, these results need to be consolidated by further studies.


  • Open Access

    Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system

    by Yang Li, Min-Min Han, Qiong He, Zi-Ang Liu, Dong Liang, Jing-Tian Hou, Yi Zhang, Yun-Feng Liu

    Exenatide once weekly combined with metformin reduced glycemic variability in type 2 diabetes by using flash glucose monitoring system